MESENTECH
Mesentech is a company focused on treating diseases and medical conditions that relate to bone. They are generating a series of products, from different, but complementary approaches that will effectively address currently difficult to treat conditions. Bone can be one of the most difficult organs to access and treat with medicines. It’s hard surface and low porosity presents challenges in adequately getting drugs to either the bone surface or to its interior. Treatment often requires adminis... tering high doses of a drug over extended periods. Not only is achievement of efficacy compromised, but also side- effects may be more prevalent and can limit treatment effectiveness. Mesentech’s lead technology is a proprietary bone targeting system that can effectively deliver small-molecule and biological drugs to the surface or to the interior of bone. Pre-clinical in-vivo models have confirmed the utility of this technology.
MESENTECH
Social Links:
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2016-01-01
Address:
Vancouver, British Columbia, Canada
Country:
Canada
Website Url:
http://www.mesentech.com
Total Employee:
1+
Status:
Active
Contact:
778-231-2500
Total Funding:
1.11 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins Mobile Non Scaleable Content
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Interline Therapeutics
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
Current Employees Featured
Founder
Investors List
Red Thread Ventures
Red Thread Ventures investment in Seed Round - Mesentech
Valhalla Angels
Valhalla Angels investment in Seed Round - Mesentech
Boutique Venture Partners
Boutique Venture Partners investment in Seed Round - Mesentech
Newton Fund
Newton Fund investment in Seed Round - Mesentech
Propel(X)
Propel(X) investment in Seed Round - Mesentech
CureDuchenne Ventures
CureDuchenne Ventures investment in Venture Round - Mesentech
Charles Hood Foundation
Charles Hood Foundation investment in Venture Round - Mesentech
The Biotechnology Industry Organization
The Biotechnology Industry Organization investment in Non Equity Assistance - Mesentech
CQDM
CQDM investment in Corporate Round - Mesentech
Adam Morley
Adam Morley investment in Seed Round - Mesentech
Official Site Inspections
http://www.mesentech.com
- Host name: res-cp3-us.yyz2.websiteservername.com
- IP address: 66.102.128.114
- Location: Hawthorne United States
- Latitude: 33.9168
- Longitude: -118.3432
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90250
More informations about "Mesentech"
Mesentech
Innovative drugs that rebuild bone lost to disease and trauma. Regenerative Medicine to reverse osteoporosis. Mesentech has developed a novel drug conjugate that can deliver bone growing …See details»
Mesentech — People
Innovative drugs that rebuild bone lost to disease and trauma. Regenerative Medicine to reverse osteoporosis. Mesentech has developed a novel drug conjugate that can deliver bone growing …See details»
Mesentech - Crunchbase Company Profile & Funding
Mesentech is a company focused on treating diseases and medical conditions that relate to bone. Mesentech may be growing as it has recently raised $15 million for Phase 1 clinical trials, …See details»
Mesentech Inc. Company Profile | Vancouver, BC, Canada
Find company research, competitor information, contact details & financial data for Mesentech Inc. of Vancouver, BC. Get the latest business insights from Dun & Bradstreet.See details»
Mesentech - LinkedIn
Mesentech is a clinical stage biotechnology company developing novel medicines that selectively distribute to the intended site of action. MES1022 is a clinical stage program for bone-repair...See details»
Mesentech - Life Sciences British Columbia
Jun 26, 2020 · Mesentech is a clinical stage biotech developing therapies for musculoskeletal disease. MES1022, currently in phase 1, is a potent anabolic that increases muscle mass and reduces fibrosis stemming from muscular dystrophy.See details»
Vancouver's Mesentech raises $15M for Phase 1 clinical …
Oct 4, 2023 · A Vancouver biotech that counts mRNA expert Pieter Cullis among its co-founders has raised $15 million to support Phase 1 clinical trials of a new drug that could be used to treat bone diseases.See details»
CQDM becomes a shareholder of Mesentech to support the …
Jun 22, 2020 · CQDM is pleased to announce an investment in Mesentech Inc., an emerging biotech based in Vancouver, British Columbia, developing a bone-targeting technology …See details»
CureDuchenne Ventures Announces Funding of …
Newport Beach, CA (November 10, 2020) – CureDuchenne Ventures, the research funding arm of CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy (DMD), …See details»
About - Mesentech
Innovative drugs that rebuild bone lost to disease and trauma. Regenerative Medicine to reverse osteoporosis. Mesentech has developed a novel drug conjugate that can deliver bone growing drugs selectively to the bone.See details»
Mesentech CEO Jonathan Polak gets down to the bone
Mar 18, 2024 · In 2018, he joined Mesentech, which has an office in Vancouver’s Mount Pleasant neighbourhood and a lab in Burnaby, as CEO. Mesentech was founded by renowned chemistry expert and SFU professor Robert Young in …See details»
Mesentech - BIO Investor Forum | BIO
Founded by the discoverer of SingulAir, Vioxx, Arcoxia, and ondanacatib while leading medicinal chemistry at Merck, Robert Young, created Mesentech to develop tissue selective prodrugs of …See details»
CQDM portfolio company Mesentech secures new capital to bring …
Montreal – November 11 2020 – CQDM congratulates Mesentech on securing additional investment to support the clinical development of their bone-targeting drug candidate MES …See details»
Mesentech — Jay Mohr joins Mesentech’s Board of Directors
Jay currently serves as Director of the T1D Exchange, a nonprofit organization dedicated to accelerating therapies and improving care and outcomes in type 1 diabetes. He is a member …See details»
Vancouver-based Biotech Company Mesentech Raises $15 Million …
Oct 10, 2023 · Vancouver-based Mesentech, a biotech company developing novel tissue-selective therapies to treat bone diseases, announced that it has dosed the first patients in its …See details»
Mesentech Doses First Patients with Investigational Drug MES1022 …
Sep 26, 2023 · Mesentech is a biotechnology company developing new therapies to treat diseases and conditions of the bone using tissue selective technologies. Its lead candidate …See details»
Mesentech — Publications
Innovative drugs that rebuild bone lost to disease and trauma. Regenerative Medicine to reverse osteoporosis. Mesentech has developed a novel drug conjugate that can deliver bone growing …See details»
Mesentech Doses First Patients with Investigational Drug MES1022 …
Sep 26, 2023 · Mesentech is a biotechnology company developing new therapies to treat diseases and conditions of the bone using tissue selective technologies. Its lead candidate …See details»
Mesentech — Science
Innovative drugs that rebuild bone lost to disease and trauma. Regenerative Medicine to reverse osteoporosis. Mesentech has developed a novel drug conjugate that can deliver bone growing …See details»
News - Mesentech
Innovative drugs that rebuild bone lost to disease and trauma. Regenerative Medicine to reverse osteoporosis. Mesentech has developed a novel drug conjugate that can deliver bone growing …See details»